How we used VR and AR to create connections between physicians and patients.
Ocular Therapeutix struck a deal worth up to $315 million to develop a new formulation of Regeneron Pharmaceuticals’ approved drug Eylea.
People with very poor vision may benefit from using a device that recognizes faces, money and text, a small study suggests.
– New Step Forward in Ophthalmology with Cell Therapy Approach – TOKYO and MASSACHUSETTS, Nov. 9, 2015 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas“) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, “Ocata“), a biotechnology company focused on the research and development of new therapies in […]
The first patient has been treated in Britain in a pioneering trial of a new treatment co-developed by Pfizer and derived from embryonic stem cells designed for patients with a condition that can cause blindness. Specialists at London’s Moorfields Eye Hospital said the operation, described as “successful”, was the first of 10 planned for participants […]